BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

362 related articles for article (PubMed ID: 11240421)

  • 1. [Endocrine disease in adrenoleukodystrophy].
    Girard S; Bruckert E; Turpin G
    Ann Med Interne (Paris); 2001 Feb; 152(1):15-26. PubMed ID: 11240421
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A two-year trial of oleic and erucic acids ("Lorenzo's oil") as treatment for adrenomyeloneuropathy.
    Aubourg P; Adamsbaum C; Lavallard-Rousseau MC; Rocchiccioli F; Cartier N; Jambaqué I; Jakobezak C; Lemaitre A; Boureau F; Wolf C
    N Engl J Med; 1993 Sep; 329(11):745-52. PubMed ID: 8350883
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Follow-up of 89 asymptomatic patients with adrenoleukodystrophy treated with Lorenzo's oil.
    Moser HW; Raymond GV; Lu SE; Muenz LR; Moser AB; Xu J; Jones RO; Loes DJ; Melhem ER; Dubey P; Bezman L; Brereton NH; Odone A
    Arch Neurol; 2005 Jul; 62(7):1073-80. PubMed ID: 16009761
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Therapy of X-linked adrenoleukodystrophy.
    Semmler A; Köhler W; Jung HH; Weller M; Linnebank M
    Expert Rev Neurother; 2008 Sep; 8(9):1367-79. PubMed ID: 18759549
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Very long chain fatty acids in X-linked adrenoleukodystrophy brain after treatment with Lorenzo's oil.
    Poulos A; Gibson R; Sharp P; Beckman K; Grattan-Smith P
    Ann Neurol; 1994 Nov; 36(5):741-6. PubMed ID: 7979219
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The effect of Lorenzo's oil on oxidative stress in X-linked adrenoleukodystrophy.
    Deon M; Wajner M; Sirtori LR; Fitarelli D; Coelho DM; Sitta A; Barschak AG; Ferreira GC; Haeser A; Giugliani R; Vargas CR
    J Neurol Sci; 2006 Sep; 247(2):157-64. PubMed ID: 16750542
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Backache as the initial symptom of adrenomyeloneuropathy].
    Benito-León J; Zamorano T; Martín-Peña G; Tapia MA; Alvarez-Linera J
    Rev Neurol; 2000 Dec 16-31; 31(12):1167-70. PubMed ID: 11205553
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Visual evoked potentials in adrenoleukodystrophy: a trial with glycerol trioleate and Lorenzo oil.
    Kaplan PW; Tusa RJ; Shankroff J; Heller J; Moser HW
    Ann Neurol; 1993 Aug; 34(2):169-74. PubMed ID: 8338341
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Is subclinical adrenal failure in adrenoleukodystrophy/adrenomyeloneuropathy reversible?
    Cappa M; Bizzarri C; Giannone G; Aiello C; Di Biase A
    J Endocrinol Invest; 2011 Nov; 34(10):753-6. PubMed ID: 21399389
    [TBL] [Abstract][Full Text] [Related]  

  • 10. X-linked adrenoleukodystrophy.
    Moser HW; Mahmood A; Raymond GV
    Nat Clin Pract Neurol; 2007 Mar; 3(3):140-51. PubMed ID: 17342190
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [X-linked adrenoleukodystrophy--2 case reports].
    Dumić M; Ille J; Plavsić V; Filipović-Grcić B; Vrljicak K; Barisić N; Roscher A
    Lijec Vjesn; 1998; 120(1-2):19-23. PubMed ID: 9650481
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dietary management of X-linked adrenoleukodystrophy.
    Moser HW; Borel J
    Annu Rev Nutr; 1995; 15():379-97. PubMed ID: 8527226
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Adrenoleukodystrophy--clinical, biochemical and therapeutic aspects].
    Skjeldal OH; Strømme P; Christensen E
    Tidsskr Nor Laegeforen; 1994 Nov; 114(28):3321-3. PubMed ID: 7809891
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Adrenoleukodystrophy].
    Kálmánchey R; Molzer B; Illés Z; Princzinger A; Sólyom J
    Orv Hetil; 1997 Apr; 138(14):867-71. PubMed ID: 9162896
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical and therapeutic aspects of adrenoleukodystrophy and adrenomyeloneuropathy.
    Moser HW
    J Neuropathol Exp Neurol; 1995 Sep; 54(5):740-5. PubMed ID: 7666063
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Progression of abnormalities in adrenomyeloneuropathy and neurologically asymptomatic X-linked adrenoleukodystrophy despite treatment with "Lorenzo's oil".
    van Geel BM; Assies J; Haverkort EB; Koelman JH; Verbeeten B; Wanders RJ; Barth PG
    J Neurol Neurosurg Psychiatry; 1999 Sep; 67(3):290-9. PubMed ID: 10449548
    [TBL] [Abstract][Full Text] [Related]  

  • 17. X-Linked adrenoleukodystrophy: overview and prognosis as a function of age and brain magnetic resonance imaging abnormality. A study involving 372 patients.
    Moser HW; Loes DJ; Melhem ER; Raymond GV; Bezman L; Cox CS; Lu SE
    Neuropediatrics; 2000 Oct; 31(5):227-39. PubMed ID: 11204280
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Progress in X-linked adrenoleukodystrophy.
    Moser H; Dubey P; Fatemi A
    Curr Opin Neurol; 2004 Jun; 17(3):263-9. PubMed ID: 15167059
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Examination of very long chain fatty acids in diagnosis of x-linked adrenoleukodystrophy].
    Stradomska TJ; Tylki-Szymańska A
    Pediatr Pol; 1996 Mar; 71(3):197-201. PubMed ID: 8966090
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Komrower Lecture. Adrenoleukodystrophy: natural history, treatment and outcome.
    Moser HW
    J Inherit Metab Dis; 1995; 18(4):435-47. PubMed ID: 7494402
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.